Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 3. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 4. 2008 Exclusive Survey—Earnings: Good news for primary care income 5. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer
Your Article Summary
See Latest ArticlesLack of killer immunoglobulin-like receptor 2DS2 (KIR2DS2) and KIR2DL2 is associated with poor responses to therapy of recurrent hepatitis C virus in liver transplant recipients
Liver Transplantation, 11/03/09
Askar M et al. – The findings support the role of natural killer and natural killer T cells in HCV clearance after LT and might be generalizable to treatment of HCV infection outside the setting of LT.
Medhat Askar, 11/08/09
| The immunogenetic factors influencing the antiviral potential of NK cells particularly activating killer cell immunoglobulin-like receptor (KIR) genes have been implicated in the outcomes of human immunodeficiency virus, herpes simplex virus, cytomegalovirus, and HCV infections. This study investigates the same paradigm in relation to the responsiveness to peginterferon/ribavirin combination therapy (Peg/RBV) in recurrent HCV infection post-transplant (LT). Results of this study provide preliminary data suggesting that the presence of KIR2DS2 and/or KIR2DL2 might be critical for an immune-enhancing effect on the responses to Peg/RBV in liver transplant recipients with recurrent HCV. Although we have studied these responses in the post-LT settings, the observed association may be generalizable to treatment of HCV infection outside the setting of LT, and can potentially provide further insight into innate anti-HCV immune mechanisms. |
Today in Transplantation...keeping you current
Receive free subspecialty "5-minute updates" via email
Outcomes After Liver Transplant in Patients Aged 70 Years or Older Compared With Those Younger Than 60 Years
Mayo Clinic Proceedings, 11/02/09
Hepatocellular carcinoma and evidence-based surgery
World Journal of Gastroenterology, 11/18/09
Systematic review of randomized trials on vasoconstrictor drugs for hepatorenal syndrome
Hepatology, 11/04/09
Sponsor
Article Search
Sponsor